Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Factors Associated Floppy Iris

This study has been completed.
Information provided by:
Baskent University Identifier:
First received: May 10, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
This study is planned to investigate the incidence of intraoperative floppy iris and its relationship with pseudoexfoliation, diabetes, hypertension as well as systemic alpha-1 adrenergic blocker use.

Pupil Constriction
Iris Floppiness
Iris Prolapsus From the Wound

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Clinical Factors Associated With Floppy Iris Signs: a Prospective Study From Two Centers

Further study details as provided by Baskent University:

Enrollment: 500
Study Start Date: November 2005
Study Completion Date: November 2006
Detailed Description:
Our aim is to investigate the incidence of intraoperative floppy iris syndrome (IFIS) signs and evaluate the relationship of IFIS signs as well as complete IFIS with pseudoexfoliation, diabetes, hypertension, and alpha-1 adrenergic blocker (A1AB) use. Five-hundred patients will be included in this prospective study. Preoperatively, pupil diameter before and after dilation, presence of pseudoexfoliation, history of diabetes, hypertension, and use of any A1AB will be recorded. Intraoperative adverse events such as pupillary constriction, iris billowing, and iris prolapse from the wound will be noted. Multinomial regression analysis will be used to evaluate the relationship of IFIS signs with pseudoexfoliation, diabetes, hypertension, and A1AB usage. According to the results we will determine the incidence of IFIS in our patient population and evaluate its relationship with alpha-1 adrenergic blocker use. We will also investigate the relationship of floppy iris problems with pseudoexfoliation, diabetes, high blood pressure.

Ages Eligible for Study:   28 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects with the diagnosis of cataract who were decided to have phacoemulsification

Exclusion Criteria:

  • Previous history of trauma or surgery of the eye, congenital ocular disease including cataract, infection, inflammation, angle closure glaucoma, or medication (topical) that might affect the size and shape of the pupil

Only the first operated eye of each patient was included.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00472888

Baskent University, Faculty of Medicine, Department of Ophthalmology
Ankara, Turkey, 06490
Sponsors and Collaborators
Baskent University
Study Chair: Rana Altan-Yaycioglu, MD Baskent University, Faculty of Medicine, Department of Ophthalmology
Study Director: Yonca A Akova, MD Baskent University, Faculty of Medicine, Department of Ophthalmology
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00472888     History of Changes
Other Study ID Numbers: KA 05/244
Study First Received: May 10, 2007
Last Updated: May 10, 2007

Keywords provided by Baskent University:
Alpha-adrenergic blockers
cataract surgery
pseudoexfoliation syndrome
diabetes mellitus

Additional relevant MeSH terms:
Constriction, Pathologic
Pathological Conditions, Anatomical
Pupil Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms processed this record on May 25, 2017